Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan (AMORE)

NCT01271374 Phase 4 UNKNOWN

The purpose of the study is to compare the effects of Azor (a combination of amlodipine and olmesartan) with Hyzaar ( a combination of losartan and hydrochlorothiazide) on the thin lining on the inside of blood vessels. These cells help keep blood vessels healthy and blood pressure normal.

Details

Lead sponsor	InVasc Therapeutics, Inc.
Phase	Phase 4
Status	UNKNOWN
Enrolment	80
Start date	2010-04
Completion	2011-12

Conditions

• Hypertension

Interventions

• amlodipine and olmesartan
• losartan and HCTZ

Primary outcomes

• Change in Central Aortic Pressure (CAP) — 14 weeks
  The primary efficacy endpoints, defined as the change from baseline of Central Aortic Systolic Pressure (CAP) and the change in brachial artery reactivity (BART) via ultrasound testing, will be compared at the end of 14 weeks of randomized treatment.

Countries

United States